Newlink genetics corp (NLNK)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash Flows From Operating Activities
Net loss

-42,989

-53,595

-71,951

-85,155

-40,381

96,017

-31,180

-23,321

-

-

-

Net loss

-

-

-

-

-

-

-

-

-18,088

-16,562

-10,207

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation

6,722

17,120

18,508

16,707

15,940

8,613

4,365

3,195

2,545

1,525

929

Depreciation and amortization

-

-

-

-

-

1,097

891

788

687

655

-

Depreciation and amortization

1,645

1,145

1,407

2,084

1,592

-

-

-

-

-

303

Amortization of right-to-use asset and change in operating lease liability

551

0

0

-

-

-

-

-

-

-

-

Forgiveness of debt

-

-

-

397

0

0

-

-

-

-

-

Impairment of fixed assets

351

0

0

3,958

0

-

-

-

-

-

-

Loss on sale of fixed assets

-20

-102

-126

0

0

0

-2

-38

0

819

-

In-process research and development expenses

-

-

-

-

-

-

-

-

0

201

0

In-process research and development expenses - Reconstitute

-

-

-

-

-

-

-

-

-

-

0

Forgiveness of debt

-

-

-

-

-

-

-

-

0

0

0

Forgiveness of notes receivable from related parties

-

-

-

-

-

-

-

-

0

350

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-2,491

-226

305

965

-3,379

-

-

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

7,561

-134

498

550

-849

60

State research and development credit receivable

-

-

-

-

-13

-316

-213

340

28

-60

-329

Interest due on notes receivable

-

-

-

-

-

-

-

-

-

-

23

Other receivables

296

-10,223

-14,350

19,139

1,672

2,388

1,132

0

416

797

1,341

Accounts payable and accrued expenses

1,979

-13,029

-15,469

24,770

245

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

7,898

843

-909

637

-528

-271

Income taxes receivable, net

421

17

5,479

-6,834

9,622

-8,892

130

0

0

-

-

Unearned revenue

0

-56

-335

-68

-12,752

14,051

0

0

-

-

-

Deferred rent

0

92

91

908

73

83

84

-576

-

-

-

Net cash used in operating activities

-30,207

-37,939

-48,281

-65,947

-24,087

-

-

-

-

-

-9,140

Accrued expenses and deferred rent

-

-

-

-

-

-

-

-

276

382

1,201

Net cash used in operating activities

-

-

-

-

-

109,068

-25,818

-20,471

-12,949

-13,270

-

Cash Flows From Investing Activities
Purchase of certificates of deposit

-

-

-

-

-

17,377

249

1,992

2,490

277

142

Maturity of certificates of deposit

-

-

-

-

-

-5,233

-1,494

-2,988

-2,269

0

0

Maturity of certificates of deposit

-

-

-

2,180

10,213

-

-

-

-

-

-

Notes receivable from related parties

-

-

-

-

-

-

-

-

0

-500

0

Purchase of equipment

0

7

43

2,246

3,995

1,700

1,386

1,323

281

2,932

1,403

Proceeds on sale of equipment

77

124

254

0

0

-

-

50

0

0

-

Cash paid for OncoRx

-

-

-

-

-

-

-

-

0

0

0

Net cash provided by investing activities

77

117

211

-66

6,218

-13,844

-141

-277

-502

-2,709

-1,545

Cash Flows From Financing Activities
Cash received from noncontrolling interest investment

-

-

-

-

-

-

-

-

0

911

40

Issuance of common stock, net of offering costs

0

0

74,416

0

13,534

27,572

66,357

158

37,574

2,082

0

Issuance of common stock under share-based compensation plans

38

294

1,407

2,222

4,206

2,327

858

1,127

-

-

-

Excess tax benefits from share-based compensation awards

-

-

-

-

6,100

4,302

0

0

-

-

-

Issuance of common stock from exercise of stock options

-

-

-

-

-

-

-

-

-

-

15

Issuance of common stock from exercise of warrants

-

-

-

-

-

-

-

-

-

-

0

Repurchase of common stock

36

275

289

82

561

222

0

4

-13

468

0

Principal payments on notes payable

-

-

-

257

194

-

-

-

-

-

-

Repayments of notes receivable for common stock

-

-

-

-

-

-

-

-

-

-25

0

Proceeds from subsidiary common stock option exercise

-

-

-

-

-

-

-

-

-

121

0

Proceeds from preferred stock

-

-

-

-

-

-

-

-

5,000

7,723

19,580

Proceeds from notes payable

-

-

-

-

-

97

0

456

0

1,100

0

Principal payments on notes payable

61

167

246

-

-

187

149

107

92

67

0

Payments under capital lease obligations

-

-

-

-

-

-

66

122

126

93

9

Net cash (used in) provided by financing activities

-59

-148

75,288

1,883

23,085

33,889

67,000

1,508

42,369

11,334

19,626

Net (decrease) increase in cash and cash equivalents

-30,189

-37,970

27,218

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-64,130

5,216

129,113

41,041

-19,240

28,918

-4,645

8,941

Supplemental disclosure of cash flows information:
Cash paid for interest

4

8

15

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

22

105

26

34

38

42

44

9

Cash paid for taxes

15

25

643

1,022

4,814

26,443

0

0

-

-

-

Proceeds from income tax refunds

425

7,057

6,651

197

13,796

0

0

-

-

-

-

Accretion on redeemable preferred stock

-

-

-

-

-

-

-

-

8

2

-

Accretion on redeemable preferred stock

-

-

-

-

-

-

-

-

-

-

0

Purchased leasehold improvements and equipment in accounts payable and accrued expenses

-

-

-

-

398

409

0

53

481

0

749

Common stock issued to shareholders of OncoRx as part of acquisition

-

-

-

-

-

-

-

-

0

932

0

Issuance of common stock dividend to Series AA preferred shareholders

-

-

-

-

-

-

-

-

1

1

1

Assets acquired under capital lease

-

-

-

231

0

0

54

0

80

282

114

Reduction of IPO offering costs

-

-

-

-

-

-

-

158

0

-

-